Tracking injectable and oral MS treatments in newly diagnosed patients

This study is following patients with relapsing multiple sclerosis who are starting approved medications to manage their condition. Researchers want to understand how well these treatments—including ofatumumab, interferon beta-1, glatiramer acetate, teriflunomide, dimethyl fumarate, and diroximel fumarate—work when used in everyday medical practice. The study will track participants' health and disease activity over about two years.

While these medications are approved and used routinely, researchers want to gather real-world information about how well they work for patients outside of controlled research settings. Understanding how the medication performs in regular clinical care helps doctors and patients make better treatment decisions.